ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

Core Viewpoint - ProQR reported a quarterly loss of $0.10 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.07, marking an earnings surprise of -42.86% [1] Financial Performance - The company posted revenues of $4.6 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 51.53$3.54 million a year ago [2] - Over the last four quarters, ProQR has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - ProQR shares have declined approximately 30.2% since the beginning of the year, contrasting with the S&P 500's decline of -4.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of$11.57 million, and for the current fiscal year, it is -$0.36 on revenues of$28.29 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which ProQR belongs, is currently in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact ProQR's stock performance [5]